Medically Licensed Mesenchymal Stem Cells for Acute Respiratory Distress Syndrom...
Medically Licensed Mesenchymal Stem Cells for Acute Respiratory Distress Syndrome.
Acute Respiratory Distress Syndrome (ARDS) is a devastating condition, which kills 40% of sufferers, resulting in hundreds of thousands of deaths worldwide annually. Despite decades of intensive research efforts, there are no clin...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PID2020-113910RB-I00
CONDICIONAMIENTO BIOFISICO DE CELULAS MADRE/ESTROMALES MESEN...
218K€
Cerrado
ALGORITM
Applying human lung tissue models to develop a personalised...
213K€
Cerrado
PTQ-10-04325
Proyecto de obtención, cultivo y caracterización de células...
75K€
Cerrado
HyalStemAge
Effect of controlled hyaluronan synthesis on the stemness of...
75K€
Cerrado
NeoCellBank
A revolutionary regenerative therapy for management of chron...
71K€
Cerrado
SAF2012-40149-C02-01
ESTUDIO PRECLINICO PARA EVALUAR CELULAS MESENQUIMALES HUMANA...
70K€
Cerrado
Información proyecto CCMI-ARDS
Duración del proyecto: 13 meses
Fecha Inicio: 2014-11-03
Fecha Fin: 2015-12-31
Líder del proyecto
UNIVERSITY OF GALWAY
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
149K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Acute Respiratory Distress Syndrome (ARDS) is a devastating condition, which kills 40% of sufferers, resulting in hundreds of thousands of deaths worldwide annually. Despite decades of intensive research efforts, there are no clinical therapeutic strategies available for this catastrophic condition. In our ERC Starter Grant, HA-NFkB-VILI, we have shown Mesenchymal Stem Cells (MSCs) to be beneficial in several relevant preclinical ARDS models.
However, for cell therapies to be successfully used in the clinic, they will need to be sourced allogeneically, culture passaged and cryofrozen for transport to the clinical site, where they can then thawed near the bedside and administered to the patient with ARDS.
This project will therefore examine the potential of cryofrozen human MSCs, manufactured at the CCMI cell therapy facility at NUI Galway, in relevant models of ARDS.
A demonstration that the cryofrozen CCMI-hMSC exhibit therapeutic potential would be a major step towards the clinical testing of these cells in patients with this devastating disease.